Epidermolysis bullosa
Drug research and approvals for epidermolysis bullosa: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 22 studies of epidermolysis bullosa are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 4 approved and 28 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 22
- Trials authorized in Canada: 2
- FDA orphan approvals: 4
- EU medicines: 2
- A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis BullosaNCT07858422 · Phase 2 · Energenesis Biomedical Co., Ltd. · starts Oct 8, 2026
- Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus PositionsNCT07780981 · Not applicable · Johns Hopkins University · starts Jul 24, 2026
- A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive…NCT07700966 · Not reported · Abeona Therapeutics, Inc · starts Jul 25, 2025
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaNCT07482787 · Phase 3 · Paradigm Therapeutics · starts Jul 21, 2026
- Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis BullosaNCT07230223 · Phase 1 / Phase 2 · Isfahan University of Medical Sciences · starts Jan 9, 2024
- GMEB-SASS: A Gene-Modified Skin Substitute for RDEB TreatmentNCT07193134 · Phase 1 / Phase 2 · CHU de Quebec-Universite Laval · starts Jan 7, 2026
- A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis…NCT07027345 · Phase 2 · BioMendics, LLC · starts Sep 11, 2025
- A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaNCT07016750 · Phase 3 · Krystal Biotech, Inc. · starts Jun 20, 2025
- A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis BullosaNCT06917690 · Phase 3 · Chiesi Farmaceutici S.p.A. · starts Apr 18, 2025
Phase 3 1
- ErythromycinBacterial 70S ribosome inhibitor
Phase 2 10
- BusulfanDNA inhibitor
- Fludarabine
- TacrolimusFK506-binding protein 1A inhibitor
- CyclophosphamideDNA inhibitor
- Diacerein
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- SerlopitantNeurokinin 1 receptor antagonist
- Thymosin
- Allantoin
Phase 1 or earlier 7
- GentamicinBacterial 70S ribosome inhibitor
- IsotretinoinRetinoic acid receptor agonist
- UbidecarenoneSupplement
- Birch triterpenes
- AlemtuzumabCAMPATH-1 antigen inhibitor
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- PaliferminFibroblast growth factor receptor 2 agonist
How its trials ended
130 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 36 whose ending is known, 31% met their primary endpoint, 6% missed it and 64% stopped early.
- Completed, result not reported4535%
- Ongoing3023%
- Status unknown1915%
- Met its primary endpoint118%
- Stopped: other or unclear118%
- Stopped: sponsor or business decision65%
- Stopped: enrollment or feasibility43%
- Missed its primary endpoint22%
- Stopped: lack of efficacy22%
| Nov 21, 2024 | Genetically-modified epidermolysis bullosa-self-assembled skin substitute (gmeb-sass) to treat patients suffering from recessive dystrophic epidermolysis…Gmeb-sass (genetically modified epidermolysis bullosa - self assembled skin… | Chu De Québec-Université Laval | Pending |
| Jan 19, 2019 | A double-blind, randomized, cross-over, feasibility trial of pregabalin for the treatment of recessive dystrophic epidermolysis bullosa-associated neuropathic…Pregabalin | The Hospital for Sick Children | Closed |
| Sep 12, 2025 | VyjuvekTreatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII… | Krystal Biotech, Inc. | Approved |
| Apr 28, 2025 | ZevaskynTreatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) | Abeona Therapeutics, Inc. | Approved |
| Dec 18, 2023 | FilsuvezTreatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age… | Chiesi Farmaceutici S.p.A. | Approved |
| May 19, 2023 | VyjuvekTreatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type… | Krystal Biotech, Inc. | Approved |
| Sep 17, 2026 | Bioresorbable amniotic membraneTreatment of epidermolysis bullosa | Diopter Technologies | Designated |
| Sep 12, 2025 | Sterile, processed, homogenized amniotic fluid solutionTreatment of epidermolysis bullosa | Eliksa Therapeutics, Inc. | Designated |
| Jan 6, 2025 | Aseptic, allogeneic, pooled human umbilical cord derived…Treatment of epidermolysis bullosa | INmune Bio Inc. | Designated |
| Dec 23, 2024 | 25 C-terminal amino acids of human thrombinTreatment of epidermolysis bullosa | Xinnate AB | Designated |
| Dec 2, 2024 | Recombinant human type VII pro-collagenTreatment of dystrophic epidermolysis bullosa | Nova Anchora, LLC | Designated |
| Mar 28, 2024 | Allantoin (5-ureidohydantoin or glyoxyldiureide)Treatment of Epidermolysis Bullosa | Paradigm Therapeutics | Designated |
| May 1, 2023 | 4-Hydroxy-4'-methyoxytolanTreatment of Epidermolysis Bullosa | BioMendics, LLC | Designated |
| Jan 31, 2023 | Human decorin, natural anti-fibrotic protein, fused to the…Treatment of epidermolysis bullosa (EB) | Theravia | Designated |
| Dec 22, 2022 | AdenineTreatment of Epidermolysis Bullosa | Energenesis Biomedical Co. Ltd. | Designated |
| Dec 21, 2020 | Highly branched poly(beta-amino ester) complexed with a…Treatment of dystrophic epidermolysis bullosa | Amryt Genetics Limited | Designated |
| Nov 5, 2020 | Epidermal stem cells genetically modified with a…Treatment of Epidermolysis Bullosa | Holostem S.r.l. | Designated |
| Apr 23, 2025 | VyjuvekBeremagene geperpavec · orphan | Krystal Biotech Netherlands B.V. | EMA ↗ |
| Jun 21, 2022 | FilsuvezBirch bark extract · orphan | Chiesi Farmaceutici S.p.A | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA